Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
8461 | 1251 | 47.6 | 77% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
12 | 4 | POLYMER SCIENCE//MATERIALS SCIENCE, PAPER & WOOD//CHEMISTRY, PHYSICAL | 1084170 |
41 | 3 | INTERNATIONAL JOURNAL OF PHARMACEUTICS//DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY//PHARMACOLOGY & PHARMACY | 99449 |
147 | 2 | SOLID LIPID NANOPARTICLES//POLYMERIC MICELLES//LIPOSOMES | 23275 |
8461 | 1 | HPMA COPOLYMER//POLYMER THER EUT//HPMA | 1251 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | HPMA COPOLYMER | authKW | 2594258 | 10% | 85% | 125 |
2 | POLYMER THER EUT | address | 813990 | 5% | 53% | 63 |
3 | HPMA | authKW | 633118 | 3% | 62% | 42 |
4 | N 2 HYDROXYPROPYLMETHACRYLAMIDE COPOLYMERS | authKW | 513609 | 2% | 96% | 22 |
5 | POLYMER THERAPEUTICS | authKW | 509522 | 4% | 43% | 49 |
6 | N 2 HYDROXYPROPYLMETHACRYLAMIDE HPMA | authKW | 292886 | 1% | 100% | 12 |
7 | PHARMACEUT PHARMACEUT CHEM | address | 258879 | 8% | 10% | 104 |
8 | POLYMER DRUG CONJUGATES | authKW | 248473 | 2% | 36% | 28 |
9 | EPR EFFECT | authKW | 225710 | 3% | 25% | 37 |
10 | DRUG DELIVERY SCI | address | 187743 | 1% | 77% | 10 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 5888 | 41% | 0% | 508 |
2 | Materials Science, Biomaterials | 5169 | 11% | 0% | 135 |
3 | Polymer Science | 3730 | 21% | 0% | 266 |
4 | Chemistry, Multidisciplinary | 1602 | 25% | 0% | 312 |
5 | Oncology | 619 | 13% | 0% | 167 |
6 | Chemistry, Organic | 336 | 9% | 0% | 112 |
7 | Engineering, Biomedical | 283 | 4% | 0% | 54 |
8 | Chemistry, Medicinal | 172 | 4% | 0% | 53 |
9 | Biochemical Research Methods | 146 | 5% | 0% | 57 |
10 | Biochemistry & Molecular Biology | 125 | 13% | 0% | 162 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | POLYMER THER EUT | 813990 | 5% | 53% | 63 |
2 | PHARMACEUT PHARMACEUT CHEM | 258879 | 8% | 10% | 104 |
3 | DRUG DELIVERY SCI | 187743 | 1% | 77% | 10 |
4 | CCCD | 171362 | 2% | 28% | 25 |
5 | MICROBIOL ONCOL | 151865 | 2% | 27% | 23 |
6 | INNOVAT CANC DIAG THER Y | 149492 | 1% | 88% | 7 |
7 | MACROMOL CHEM | 134375 | 12% | 4% | 150 |
8 | UTAH PHOTOMED | 122036 | 0% | 100% | 5 |
9 | PHARMACEUT PHARMACEUT CHEM CCCD | 122026 | 1% | 50% | 10 |
10 | CLIN COOPERAT UNIT RADIOTHER EUT ONCOL | 104130 | 1% | 53% | 8 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF CONTROLLED RELEASE | 70994 | 12% | 2% | 147 |
2 | JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS | 55698 | 4% | 5% | 45 |
3 | JOURNAL OF DRUG TARGETING | 26339 | 3% | 3% | 41 |
4 | ADVANCED DRUG DELIVERY REVIEWS | 11142 | 3% | 1% | 35 |
5 | MACROMOLECULAR BIOSCIENCE | 10842 | 2% | 1% | 30 |
6 | BIOCONJUGATE CHEMISTRY | 9003 | 3% | 1% | 43 |
7 | MOLECULAR PHARMACEUTICS | 8397 | 3% | 1% | 33 |
8 | BIOMACROMOLECULES | 6980 | 4% | 1% | 44 |
9 | PHARMACEUTICAL RESEARCH | 3078 | 3% | 0% | 32 |
10 | CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS | 2684 | 0% | 2% | 6 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | HPMA COPOLYMER | 2594258 | 10% | 85% | 125 | Search HPMA+COPOLYMER | Search HPMA+COPOLYMER |
2 | HPMA | 633118 | 3% | 62% | 42 | Search HPMA | Search HPMA |
3 | N 2 HYDROXYPROPYLMETHACRYLAMIDE COPOLYMERS | 513609 | 2% | 96% | 22 | Search N+2+HYDROXYPROPYLMETHACRYLAMIDE+COPOLYMERS | Search N+2+HYDROXYPROPYLMETHACRYLAMIDE+COPOLYMERS |
4 | POLYMER THERAPEUTICS | 509522 | 4% | 43% | 49 | Search POLYMER+THERAPEUTICS | Search POLYMER+THERAPEUTICS |
5 | N 2 HYDROXYPROPYLMETHACRYLAMIDE HPMA | 292886 | 1% | 100% | 12 | Search N+2+HYDROXYPROPYLMETHACRYLAMIDE+HPMA | Search N+2+HYDROXYPROPYLMETHACRYLAMIDE+HPMA |
6 | POLYMER DRUG CONJUGATES | 248473 | 2% | 36% | 28 | Search POLYMER+DRUG+CONJUGATES | Search POLYMER+DRUG+CONJUGATES |
7 | EPR EFFECT | 225710 | 3% | 25% | 37 | Search EPR+EFFECT | Search EPR+EFFECT |
8 | N 2 HYDROXYPROPYLMETHACRYLAMIDE | 175722 | 1% | 60% | 12 | Search N+2+HYDROXYPROPYLMETHACRYLAMIDE | Search N+2+HYDROXYPROPYLMETHACRYLAMIDE |
9 | MESOCHLORIN E6 | 149492 | 1% | 88% | 7 | Search MESOCHLORIN+E6 | Search MESOCHLORIN+E6 |
10 | MACROMOLECULAR PRODRUG | 136663 | 1% | 40% | 14 | Search MACROMOLECULAR+PRODRUG | Search MACROMOLECULAR+PRODRUG |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | ULBRICH, K , SUBR, V , (2010) STRUCTURAL AND CHEMICAL ASPECTS OF HPMA COPOLYMERS AS DRUG CARRIERS.ADVANCED DRUG DELIVERY REVIEWS. VOL. 62. ISSUE 2. P. 150-166 | 145 | 81% | 85 |
2 | ULBRICH, K , HOLA, K , SUBR, V , BAKANDRITSOS, A , TUCEK, J , ZBORIL, R , (2016) TARGETED DRUG DELIVERY WITH POLYMERS AND MAGNETIC NANOPARTICLES: COVALENT AND NONCOVALENT APPROACHES, RELEASE CONTROL, AND CLINICAL STUDIES.CHEMICAL REVIEWS. VOL. 116. ISSUE 9. P. 5338 -5431 | 204 | 28% | 16 |
3 | KOPECEK, J , KOPECKOVA, P , (2010) HPMA COPOLYMERS: ORIGINS, EARLY DEVELOPMENTS, PRESENT, AND FUTURE.ADVANCED DRUG DELIVERY REVIEWS. VOL. 62. ISSUE 2. P. 122-149 | 96 | 63% | 212 |
4 | LAMMERS, T , (2010) IMPROVING THE EFFICACY OF COMBINED MODALITY ANTICANCER THERAPY USING HPMA COPOLYMER-BASED NANOMEDICINE FORMULATIONS.ADVANCED DRUG DELIVERY REVIEWS. VOL. 62. ISSUE 2. P. 203-230 | 120 | 60% | 46 |
5 | KOPECEK, J , (2013) POLYMER-DRUG CONJUGATES: ORIGINS, PROGRESS TO DATE AND FUTURE DIRECTIONS.ADVANCED DRUG DELIVERY REVIEWS. VOL. 65. ISSUE 1. P. 49-59 | 83 | 57% | 114 |
6 | DUNCAN, R , (2009) DEVELOPMENT OF HPMA COPOLYMER-ANTICANCER CONJUGATES: CLINICAL EXPERIENCE AND LESSONS LEARNT.ADVANCED DRUG DELIVERY REVIEWS. VOL. 61. ISSUE 13. P. 1131-1148 | 71 | 89% | 111 |
7 | YANG, JY , KOPECEK, J , (2014) MACROMOLECULAR THERAPEUTICS.JOURNAL OF CONTROLLED RELEASE. VOL. 190. ISSUE . P. 288 -303 | 94 | 53% | 18 |
8 | YANG, JY , KOPECEK, J , (2016) DESIGN OF SMART HPMA COPOLYMER-BASED NANOMEDICINES.JOURNAL OF CONTROLLED RELEASE. VOL. 240. ISSUE . P. 9 -23 | 100 | 48% | 2 |
9 | KOPECEK, J , KOPECKOVA, P , MINKO, T , LU, ZR , (2000) HPMA COPOLYMER-ANTICANCER DRUG CONJUGATES: DESIGN, ACTIVITY, AND MECHANISM OF ACTION.EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS. VOL. 50. ISSUE 1. P. 61 -81 | 77 | 69% | 363 |
10 | MINKO, T , (2010) HPMA COPOLYMERS FOR MODULATING CELLULAR SIGNALING AND OVERCOMING MULTIDRUG RESISTANCE.ADVANCED DRUG DELIVERY REVIEWS. VOL. 62. ISSUE 2. P. 192-202 | 75 | 66% | 18 |
Classes with closest relation at Level 1 |